AstraZeneca’s asthma drug Fasenra looks promising for a set of rare chronic immune diseases

[cafead]

via Just 16 months after the FDA approved AstraZeneca’s Fasenra for a severe form of asthma, investigators at the NIH have found that the drug appears to hold great promise for treating rare chronic immune disorders called hypereosinophilic syndromes, or HES.

article source